Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those relapsing later preferentially develop mutations i...

Full description

Bibliographic Details
Main Authors: Beth O. Van Emburgh, Sabrina Arena, Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Giorgio Corti, Benedetta Mussolin, Federica Baldi, Michela Buscarino, Alice Bartolini, Emanuele Valtorta, Joana Vidal, Beatriz Bellosillo, Giovanni Germano, Filippo Pietrantonio, Agostino Ponzetti, Joan Albanell, Salvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Clara Montagut, Alberto Bardelli
Format: Article
Language:English
Published: Nature Portfolio 2016-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms13665

Similar Items

Similar Items